These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The multifactorial aetiology and management of premenstrual dysphoric disorder with leuprorelin acetate. Dunphy L; Boyle S; Wood F BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38160030 [TBL] [Abstract][Full Text] [Related]
7. Treatment of premenstrual dysphoric disorder. Rapkin AJ; Lewis EI Womens Health (Lond); 2013 Nov; 9(6):537-56. PubMed ID: 24161307 [TBL] [Abstract][Full Text] [Related]
8. [The efficiency of oral contraception containing drospirenone in treating symptoms of premenstrual syndrome or premenstrual dysphoric disorder in gyneacology practice]. Svojanovská K Ceska Gynekol; 2010 Oct; 75(5):474-80. PubMed ID: 21374928 [TBL] [Abstract][Full Text] [Related]
9. Premenstrual dysphoric disorder: burden of illness and treatment update. Pearlstein T; Steiner M J Psychiatry Neurosci; 2008 Jul; 33(4):291-301. PubMed ID: 18592027 [TBL] [Abstract][Full Text] [Related]
10. Treatment of premenstrual dysphoric disorder with the GABA Bixo M; Ekberg K; Poromaa IS; Hirschberg AL; Jonasson AF; Andréen L; Timby E; Wulff M; Ehrenborg A; Bäckström T Psychoneuroendocrinology; 2017 Jun; 80():46-55. PubMed ID: 28319848 [TBL] [Abstract][Full Text] [Related]
11. [Premenstrual syndrome and premenstrual dysphoric disorder]. Kovács Z; Hegyi G; Szőke H Orv Hetil; 2022 Jun; 163(26):1023-1031. PubMed ID: 35895486 [TBL] [Abstract][Full Text] [Related]
12. Current status and problems in the diagnosis and treatment of premenstrual syndrome and premenstrual dysphoric disorder from the perspective of obstetricians and gynecologists in Japan. Yoshimi K; Inoue F; Odai T; Shirato N; Watanabe Z; Otsubo T; Terauchi M; Takeda T J Obstet Gynaecol Res; 2023 May; 49(5):1375-1382. PubMed ID: 36822597 [TBL] [Abstract][Full Text] [Related]
14. What's Stopping Us? Using GnRH Analogs With Stable Hormone Addback in Treatment-Resistant Premenstrual Dysphoric Disorder: Practical Guidelines and Risk-Benefit Analysis for Long-term Therapy. Wagner-Schuman M; Kania A; Barone JC; Ross JM; Mulvihill A; Eisenlohr-Moul TA J Clin Psychiatry; 2023 Jun; 84(4):. PubMed ID: 37341478 [No Abstract] [Full Text] [Related]
15. Premenstrual syndrome and premenstrual dysphoric disorder in adolescents. Itriyeva K Curr Probl Pediatr Adolesc Health Care; 2022 May; 52(5):101187. PubMed ID: 35534402 [TBL] [Abstract][Full Text] [Related]
16. ShuYu capsule alleviates emotional and physical symptoms of premenstrual dysphoric disorder: Impact on ALLO decline and GABA Geng X; Wang X; Liu K; Xing Y; Xu J; Li Z; Zhang H; Hu M; Gao P; Chen D; Liu W; Li K; Wei S Phytomedicine; 2024 Jul; 130():155549. PubMed ID: 38810551 [TBL] [Abstract][Full Text] [Related]
17. Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD. Jackson C; Pearson B; Girdler S; Johnson J; Hamer RM; Killenberg S; Meltzer-Brody S Hum Psychopharmacol; 2015 Nov; 30(6):425-34. PubMed ID: 26193781 [TBL] [Abstract][Full Text] [Related]
18. The pharmacologic management of premenstrual dysphoric disorder. Rapkin AJ; Winer SA Expert Opin Pharmacother; 2008 Feb; 9(3):429-45. PubMed ID: 18220493 [TBL] [Abstract][Full Text] [Related]